Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors

References

• Davoli T, Xu AW, Mengwasser KE, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013;155:948–962.
   PubMed Web of Science ®Google Scholar
• Taylor AM, Shih J, Ha G, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33:676–89 e3.
   PubMed Web of Science ®Google Scholar
• Ben-David U, Amon A. Context is everything: aneuploidy in cancer. Nat Rev Genet. 2019;21(1):44–62.
   PubMed Web of Science ®Google Scholar
• Tschaharganeh DF, Bosbach B, Lowe SW. Coordinated tumor suppression by chromosome 8p. Cancer Cell. 2016;29:617–619.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Cai Y, Crowther J, Pastor T, et al. Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism. Cancer Cell. 2016;29:751–766.
   PubMed Web of Science ®Google Scholar
• Lebok P, Mittenzwei A, Kluth M, et al. 8p deletion is strongly linked to poor prognosis in breast cancer. Cancer Biol Ther. 2015;16:1080–1087.
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.
   PubMed Web of Science ®Google Scholar
• Delaney JR, Patel CB, Willis KM, et al. Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer. Nat Commun. 2017;8:14423.
   PubMed Web of Science ®Google Scholar
• Engler DA, Gupta S, Growdon WB, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One. 2012;7:e30996.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Liu X, Dmitrovsky E. New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy. Annu Rev Pharmacol Toxicol. 2019;59:361–377.
   PubMed Web of Science ®Google Scholar
• Tang YC, Williams BR, Siegel JJ, et al. Identification of aneuploidy-selective antiproliferation compounds. Cell. 2011;144:499–512.
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD; Cancer Genome Atlas Research N. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
   PubMed Web of Science ®Google Scholar
• Delaney JR, Stupack DG. Whole genome pathway analysis identifies an association of cadmium response gene loss with copy number variation in mutant p53 bearing uterine endometrial carcinomas. PLoS One. 2016;11:e0159114.
   PubMed Web of Science ®Google Scholar
• Campbell KR, Steif A, Laks E, et al. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Genome Biol. 2019;20:54.
   PubMed Web of Science ®Google Scholar
• Penner-Goeke S, Lichtensztejn Z, Neufeld M, et al. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genet. 2017;13:e1006707.
   PubMed Web of Science ®Google Scholar
• Andriani GA, Maggi E, Pique D, et al. A direct comparison of interphase FISH versus low-coverage single cell sequencing to detect aneuploidy reveals respective strengths and weaknesses. Sci Rep. 2019;9:10508.
   PubMed Web of Science ®Google Scholar
• Longo DL. Personalized Medicine for Primary Treatment of Serous Ovarian Cancer. N Engl J Med. 2019;381:2471–2474.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403–2415.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428.
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489–494.
   PubMed Web of Science ®Google Scholar
• Shih AJ, Menzin A, Whyte J, et al. Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS One. 2018;13:e0206785.
   PubMed Web of Science ®Google Scholar
• Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411–420.
   PubMed Web of Science ®Google Scholar
• Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888–902 e21.
   PubMed Web of Science ®Google Scholar
• Ortega MA, Poirion O, Zhu X, et al. Using single-cell multiple omics approaches to resolve tumor heterogeneity. Clin Transl Med. 2017;6:46.
   PubMed Web of Science ®Google Scholar
• Olshen AB, Venkatraman ES, Lucito R, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5:557–572.
   PubMed Web of Science ®Google Scholar
• Delaney JR, Patel CB, Bapat J, et al. Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors. PLoS Genet. 2020;16:e1008558.
   PubMed Web of Science ®Google Scholar
• Ortell KK, Switonski PM, Delaney JR. FairSubset: A tool to choose representative subsets of data for use with replicates or groups of different sample sizes. J Biol Methods. 2019;6:e118.
   PubMedGoogle Scholar
• Sack LM, Davoli T, Li MZ, et al. Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns. Cell. 2018;173:499–514 e23.
   PubMed Web of Science ®Google Scholar
• Solimini NL, Xu Q, Mermel CH, et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012;337:104–109.
   PubMed Web of Science ®Google Scholar
• Delaney JR, Patel C, McCabe KE, et al. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. Oncotarget. 2015;6:31104–31118.
   PubMed Web of Science ®Google Scholar
• Davis MA, Delaney JR, Patel CB, et al. Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings. Drug Des Devel Ther. 2016;10:1837–1846.
   PubMed Web of Science ®Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598–610.
   PubMed Web of Science ®Google Scholar
• Ward KK, Tancioni I, Lawson C, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013;30:579–594.
   PubMed Web of Science ®Google Scholar
• Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, et al. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Elife. 2019;8:e47327.
   Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134–1140.
   PubMed Web of Science ®Google Scholar
• Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298–306.
   PubMed Web of Science ®Google Scholar
• Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129:439–447.
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Murali R, Tin A, et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 2018;7. DOI:10.7554/eLife.37294
   PubMed Web of Science ®Google Scholar
• Correa RJ, Valdes YR, Shepherd TG, et al. Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro. J Ovarian Res. 2015;8:52.
   PubMed Web of Science ®Google Scholar
• Fremont S, Gerard A, Galloux M, et al. Beclin-1 is required for chromosome congression and proper outer kinetochore assembly. EMBO Rep. 2013;14:364–372.
   PubMed Web of Science ®Google Scholar
• Park JM, Tougeron D, Huang S, et al. Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PLoS One. 2014;9:e100819.
   PubMed Web of Science ®Google Scholar
• Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93.
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–339.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen C, Xu Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016;531:471–475.
   PubMed Web of Science ®Google Scholar
• Zhang S, Mercado-Uribe I, Xing Z, et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33:116–128.
   PubMed Web of Science ®Google Scholar
• White-Gilbertson S, Lu P, Jones CM, et al. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis. Cancer Med. 2020;9:3142–3152.
   PubMed Web of Science ®Google Scholar
• Haraksingh RR, Abyzov A, Urban AE. Comprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation (CNV) analysis in humans. BMC Genomics. 2017;18:321.
   PubMed Web of Science ®Google Scholar
• Group PTC, Calabrese C, Davidson NR, Demircioglu D. et al. Genomic basis for RNA alterations in cancer. Nature. 2020;578:129–136.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166:755–765.
   PubMed Web of Science ®Google Scholar
• Coward J, Harding A. Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer. Front Oncol. 2014;4:123.
   PubMedGoogle Scholar
• Schulze S, Petersen I. Gender and ploidy in cancer survival. Cell Oncol (Dordr). 2011;34:199–208.
   PubMed Web of Science ®Google Scholar